Fundraising Fox
Clay Thorp
InvestorGeneral Partner at Hatteras Venture Partners · Board director at PIPr Therapeutics · Board director at Orig3N · Board director at GeneCentric
Chapel Hill, North Carolina
Writes $100K – $5M checks · typically $1.5M
Find your path to Clay
114 people in our graph share verified history with Clay — schools, employers, funds. One of them is your warm intro.
About
Clay B. Thorp grew a $3M experiment into $175–200M+ funds while deliberately staying focused on seed and early-stage life sciences, combining operator experience, NAS SBIR/STTR policy service, and biotech commentary.
Contact· self-published, not guessed
Invests in
AgTechAI & Machine LearningBiotechFoodTechHealthtechMedical Devices
Board director at PIPr Therapeutics
Intro paths
In turn, Clay can intro founders to PIPr Therapeutics's investors below.
PIPr Therapeutics's investors · 1
Board director at Orig3N
Intro paths
In turn, Clay can intro founders to Orig3N's investors below.
Orig3N's investors · 1
Co-founders at Orig3N
Board director at GeneCentric
Intro paths
In turn, Clay can intro founders to GeneCentric's investors below.
GeneCentric's investors · 2
Co-founders at GeneCentric
Experience
- Hatteras Venture PartnersGeneral Partnercurrent2000 — presentDurham, North Carolina, United States
- BioVista Capital (now Hatteras BioCapital)General Partner2002 — 2004
- Catalysta PartnersGeneral Partner2000 — 2004
- Novalon Pharmaceutical CorporationDirector, Corporate Development1996 — 2000
- Novalon Pharmaceuitcal CorpDirector of Corporate Development1996 — 2000
- Student Coalition for Action in Literacy Education (SCALE)Co-Director1990 — 1992
Deals · 3
Clearside BiomedicalBoard seat
via Hatteras Venture Partners · filed Dec 2019 · $3.3M raise
PhaseBio PharmaceuticalsBoard seat
via Hatteras Venture Partners · filed Jul 2015 · $42M raise
G1 TherapeuticsBoard seat
via Hatteras Venture Partners · filed Feb 2015 · $33M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Investor
ArtuslabsCREATE MedicinesCuroverseEmpliantGeneCentricLysosomal TherapeuticsPathfinder TherapeuticsRodin TherapeuticsTen63 Therapeutics
Sources: SEC Form D filings · curated public sources.
What founders say
No founder feedback on Clay Thorp yet.
Colleagues at Hatteras Venture Partners
Network5
Investors connected to Clay in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Clay Thorp?
- Clay B. Thorp grew a $3M experiment into $175–200M+ funds while deliberately staying focused on seed and early-stage life sciences, combining operator experience, NAS SBIR/STTR policy service, and biotech commentary.
- Where does Clay Thorp work?
- Clay Thorp is General Partner at Hatteras Venture Partners and Board director at PIPr Therapeutics and Board director at Orig3N and Board director at GeneCentric.
- What does Clay Thorp invest in?
- Clay Thorp invests in AgTech, AI & Machine Learning, Biotech, FoodTech, Healthtech, Medical Devices.
- What check size does Clay Thorp write?
- Clay Thorp typically writes checks of $100K – $5M.
- What boards does Clay Thorp sit on?
- Clay Thorp holds tracked board seats at Clearside Biomedical, G1 Therapeutics, PhaseBio Pharmaceuticals.
- What companies has Clay Thorp invested in?
- Investments tracked here include Artuslabs, Clearside Biomedical, CREATE Medicines, Curoverse, Empliant, GeneCentric, Lysosomal Therapeutics, Pathfinder Therapeutics, Rodin Therapeutics, Ten63 Therapeutics.
- Where did Clay Thorp go to school?
- Clay Thorp studied at Harvard Kennedy School (Master’s Degree, Public Policy - Business/Government concentration); The University of North Carolina at Chapel Hill (BA, Math and Art History); Harvard Kennedy School.
Same school
Also attended Harvard Kennedy School369
+ 363 more
Also attended The University of North Carolina at Chapel Hill499
+ 493 more